To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
BiolexBiolex Therapeutics is a biotechnology firm in the Research Triangle of North Carolina. The company focuses on formation of difficult to synthesize proteins in Lemna, a duckweed.[1] The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex has developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna.[2] Therapeutic glycosylated proteins, such as monoclonal antibodies, have been produced by the Lemna system at Biolex.[3] Additional recommended knowledgeBiolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired LemnaGene SA of Lyon, France in 2005.[4] Biolex is a privately held company backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners. The term "plantibody" is trademarked by Biolex. References
|
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Biolex". A list of authors is available in Wikipedia. |